FULC — Fulcrum Therapeutics Share News
0.000.00%
Last trade - 00:00- $280.77m
- -$38.07m
Fulcrum Therapeutics Inc expected to post a loss of 43 cents a share - Earnings Preview
Brief: Fulcrum Therapeutics - As Of September 30, 2023, Cash, Cash Equivalents, And Marketable Securities Were $257.1 Million
Brief: Fulcrum Therapeutics Q3 Basic EPS USD -0.39
Fulcrum Therapeutics Inc expected to post a loss of 43 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-GMS, Phenomex, Premier
U.S. STOCKS ON THE MOVE-AMTD Digital, BioXcel, Hasbro
U.S. STOCKS ON THE MOVE-AppLovin, SolarEdge, Fabrinet
U.S. STOCKS ON THE MOVE-Fulcrum, iQIYI, MINISO
Fulcrum jumps as US FDA lifts hold on sickle cell disease therapy
Fulcrum Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Fulcrum Therapeutics Appoints Chief Financial Officer
Brief: Fulcrum Therapeutics Q2 Basic EPS USD -0.38
U.S. STOCKS ON THE MOVE-Hecla Mining, Shineco, Fulcrum Therapeutics
Brief: Fulcrum Therapeutics Signs Exclusive Global License Agreement In Rare Hematology
U.S. RESEARCH ROUNDUP-Albemarle, Ellington Financial, Savara
Fulcrum Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Fulcrum Therapeutics Announces Financial Results For The First Quarter 2023
Brief: Fulcrum Therapeutics Appoints Alex C. Sapir Chief Executive Officer
Fulcrum Therapeutics Inc expected to post a loss of 46 cents a share - Earnings Preview